Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: blankmind who wrote (9416)	6/9/1998 5:01:00 PM
From: John W. Andrews	Read Replies (2) \| Respond to of 23519

VVUS had 44 million cash as of last Q.....losses right now are estimated at (.15/sh) this quarter so lets make at a loss of 30 cents/share times 34 million equals.....roughly 11 million cash burn...no problem making into Q3 and 4 .....as long as its not into the 50-75 cent loss area.... Regards Dr. Andrews

To: blankmind who wrote (9416)	6/9/1998 5:01:00 PM
From: g.w. barnard	Read Replies (2) \| Respond to of 23519

blank, don't forget this from the 10k. The Company anticipates that its existing capital resources may not be sufficient to support the Company's operations through the commercial introduction of MUSE (alprostadil) in all international markets or for the introduction of any additional future products. During 1998, the Company anticipates using financing sources, such as receivables financing, lease financing and credit lines, to provide additional capital resources. The Company may also be required to issue additional equity or debt securities and may use other financing sources including, but not limited to corporate alliances and lease financing to fund the future development and possible commercial launch of its future products. The sale of additional equity securities would result in additional dilution to the Company's stockholders. The Company's working capital and additional funding requirements will depend upon numerous factors, including: (i) the level of resources that the Company devotes to sales and marketing capabilities; (ii) the level of resources that the Company devotes to expanding manufacturing capacity; (iii) the activities of competitors; (iv) the progress of the Company's research and development programs; (v) the timing and results of preclinical testing and clinical trials; (vi) technological advances; and (vii) results of operations. they will need some cash burn rate 6 mil qtr. (i am anticipating 3rd and 4th qtr to be positive and lessen the demand for additional funding via equity financing). am hoping they can meet obligations by lease fin, accts rec, or credit from traditional sources. gw ps way oversold at this level.